Grant: Idea to Innovation
University of Calgary
$145,472.00
Mass spec studio: business intelligence software for the international laboratory industry (a Phase IIb project)
FY 2020-21
Summary
Many chronic human conditions remain poorly treated. Diseases like cancer, arthritis, gastrointestinal disorders, kidney disease and many others lack effective therapies. It is the goal of modern medicine to develop drugs for these diseases and improve the health-span of society. The effort involves fundamental research into the nature of disease, drug product discovery and development, and drug monitoring. All these activities stretch over multiple industries and rely heavily upon scientific tools of molecular analysis, like the mass spectrometer. These tools are used to discover drugs, shorten the path to their development, ensure product safety and determine if the drugs are working in the population. Mass spectrometers, like many modern tools of analysis, generate complex data streams that are difficult to interpret. The current project will launch a powerful development framework called the Mass Spec Studio to create software products for data analytics. This proprietary framework is an app development generator that supports mass spectrometry and can be expanded to other techniques. The project will deliver its flagship product (HXauto) for measuring the safety and stability of biologics, an important new class of drug therapy. Successful commercialization of HXauto will validate our business plans and lead to a new Canadian software design firm in partnership with a major international life sciences company.
Program
Idea to Innovation
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
557341-2020
Name nom
Schriemer, David
Department département
Biochemistry and Molecular Biology
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
145472
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
801
Area of application group en
Information and communication services
Area of application group fr
Services d'information et de télécommunications
Area of application en
Computer software
Area of application fr
Logiciel
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Mass spec studio: business intelligence software for the international laboratory industry (a Phase IIb project)
Keyword
NSERC
Application summary
Many chronic human conditions remain poorly treated. Diseases like cancer, arthritis, gastrointestinal disorders, kidney disease and many others lack effective therapies. It is the goal of modern medicine to develop drugs for these diseases and improve the health-span of society. The effort involves fundamental research into the nature of disease, drug product discovery and development, and drug monitoring. All these activities stretch over multiple industries and rely heavily upon scientific tools of molecular analysis, like the mass spectrometer. These tools are used to discover drugs, shorten the path to their development, ensure product safety and determine if the drugs are working in the population. Mass spectrometers, like many modern tools of analysis, generate complex data streams that are difficult to interpret. The current project will launch a powerful development framework called the Mass Spec Studio to create software products for data analytics. This proprietary framework is an app development generator that supports mass spectrometry and can be expanded to other techniques. The project will deliver its flagship product (HXauto) for measuring the safety and stability of biologics, an important new class of drug therapy. Successful commercialization of HXauto will validate our business plans and lead to a new Canadian software design firm in partnership with a major international life sciences company.